公开(公告)号：US20180021345A1

公开(公告)日：2018-01-25

申请号：US15673155

申请日：2017-08-09

Applicant: Novartis AG

Inventor： David BEATTIE ,  Urs BAETTIG ,  Darren Mark LE GRAND ,  Andrew Stuart LISTER ,  Jeffrey MCKENNA ,  David William PEARCE ,  David Andrew SANDHAM ,  Oliver Ross STEWARD ,  Christopher THOMSON

IPC: A61K31/551 ,  C07D401/12 ,  A61K31/445 ,  C07D413/12 ,  A61K31/5513 ,  A61K45/06 ,  A61K31/504 ,  C07D401/10 ,  A61K31/5377 ,  A61K31/454 ,  A61K31/439 ,  C07D405/12 ,  C07D417/10 ,  C07D417/14 ,  A61K31/4545 ,  C07D403/10 ,  C07D413/14 ,  A61K31/4245 ,  C07D471/08 ,  C07D403/12 ,  A61K31/427 ,  C07D413/10 ,  C07D401/14 ,  A61K31/506 ,  C07D407/12 ,  C07D257/04 ,  C07D403/14 ,  A61K31/45 ,  A61K31/496 ,  A61K31/41

CPC classification number: A61K31/551 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/439 ,  A61K31/445 ,  A61K31/45 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/504 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5513 ,  A61K45/06 ,  C07D257/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D407/12 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14 ,  C07D417/10 ,  C07D417/14 ,  C07D471/08 ,  A61K2300/00

Abstract: The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.

公开(公告)号：US20220211815A1

公开(公告)日：2022-07-07

申请号：US16966514

申请日：2019-02-01

Applicant: Novartis AG ,  Chinook Therapeutics, Inc.

Inventor： Nadja KOPP ,  Justin LEONG ,  Jeffrey MCKENNA ,  Chudi Obioma NDUBAKU ,  Maria PINZON-ORTIZ ,  Xianhui RONG ,  Ryan SULLIVAN

IPC: A61K38/20 ,  A61K38/17 ,  A61K45/06 ,  A61P35/00

Abstract: The present disclosure relates to a pharmaceutical composition comprising a STING agonist molecule in combination with an IL-15/IL-15Ra complex. The present combination can be administered independently or separately, in a quantity which is therapeutically effective for the treatment of cancer. Also provided is the use of such a combination for the manufacture of a medicament; the use of such a combination as a medicine; a kit of parts comprising such a combination; and a method of treatment of such a combination.

公开(公告)号：US20190185511A1

公开(公告)日：2019-06-20

申请号：US16315612

申请日：2017-07-01

Applicant: ADURO BIOTECH, INC. ,  NOVARTIS AG

Inventor： David Braun KANNE ,  Chudi Obioma NDUBAKU ,  Jacob Robert BRUML ,  Thanh Ngoc Lan LE ,  Jeffrey MCKENNA ,  George Scott TRIA ,  Stephen CANHAM

IPC: C07H21/00 ,  C12N15/113 ,  A61P35/00 ,  A61K9/00 ,  A61P1/00 ,  A61P17/06 ,  A61P3/10 ,  A61P37/06 ,  A61P31/00

CPC classification number: C07H21/00 ,  A61K9/0019 ,  A61K45/06 ,  A61P1/00 ,  A61P3/10 ,  A61P17/06 ,  A61P31/00 ,  A61P35/00 ,  A61P37/06 ,  C12N15/113

Abstract: The present invention provides highly active locked nucleic acid cyclic-dinucleotide (LNA-CDN) immune stimulators that activate DCs via the cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the LNA-CDNs of the present invention are provided in the form of a composition comprising one or more cyclic dinucleotides that induce human STING-dependent type I interferon production, wherein the cyclic dinucleotides present in the composition have at least one 2′, 4′ locked nucleic acids within the cyclic dinucleotide.